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The effect of pacing-induced myocardial ischemia on
platelet activation and fibrin formation was investigated
in seven patients with severe proximal lesions of the left
anterior descending coronary artery to determine if acute
ischemia activates the coagulation system. Fibrin for-
mation was assessed from plasma levelsof fibrinopeptide
A. Platelet activation was assessed by levels of platelet
factor 4, beta-thromboglobulin and thromboxane B2•
Plasma levels were measured before, during and after
acute myocardial ischemia induced by rapid atrial pac-
ing. Blood samples were collected from the ascending
aorta and from the great cardiac vein through heparin-
bonded catheters. The occurrence of anterior myo-
cardial ischemia was established by electrocardiography
and by myocardial lactate extraction.
It is well established that acute myocardial infarction is
usually associated with angiographically demonstrable coro-
nary artery occlusion (I). Successful recanalization of oc-
cluded coronary arteries with specific thrombolytic agents
such as streptokinase (2,3) and tissue plasminogen activator
(4) has demonstrated that the occlusion is, in most cases,
due to thrombus. The presence of coronary thrombus implies
that the coagulation mechanism has been activated and
thrombin has been generated to convert fibrinogen to fibrin.
Several studies (5-7) in which platelet proteins, thrornbox-
ane 8 2 or fibrinopeptides were measured have suggested
that acute myocardial infarction is associated with activation
of the hemostatic system.
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No significant transmyocardial gradients in the levels
of fibrinopeptide A, platelet factor 4, beta-thrombo-
globulin or thromboxane B2 were found at rest, during
ischemia or in the recovery period, and levelsin the great
cardiac vein did not change in response to ischemia.
These data indicate that pacing-induced myocardial
ischemia does not result in release of fibrinopeptide A,
platelet factor 4, beta-thromboglobulin or thromboxane
B2 into the coronary circulation, and imply that acute
ischemia does not induce platelet activation or fibrin
formation in the coronary circulation.
(J Am Coll Cardiol1987;lO:40-S)
Whether acute myocardial ischemia can trigger the
thrombotic process in the coronary circulation is an impor-
tant and unresolved issue. We have previously observed (8)
in patients with angiographically documented coronary ar-
tery disease who were studied at rest that activation of plate-
lets or fibrin formation could not be detected by measure-
ments made in peripheral blood. Fibrinopeptide A was assayed
to detect fibrin I formation, and levels of platelet factor 4,
beta-thromboglobulin and thromboxane 8 2 were measured
to detect in vivo platelet activation. In a subsequent study
(9) we observed that these levels were not significantly
elevated in the peripheral venous blood of patients with
coronary artery disease during exercise-induced myocardial
ischemia. Although these results suggest that the hemostatic
mechanism is not activated during induced myocardial isch-
emia, it is possible that measurements of platelet proteins
and fibrinopeptides in peripheral venous blood may be in-
adequate for the detection of activation of the hemostatic
system in the coronary circulation.
A more direct approach is to selectively sample the coro-
nary venous effluent from the ischemic myocardium, but
this approach requires meticulous technique to avoid arti-
factual platelet activation and fibrin formation. Two groups
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of investigators (10, II) have reported that thromboxane B2
levels are elevated in coronary sinus blood collected with
woven Dacron catheters from patients during pacing-in-
duced myocardial ischemia. We have demonstrated that these
catheters induce fibrin formation and platelet adhesion to
catheter surfaces, artifactually elevating fibrinopeptide A,
platelet factor 4, beta-thromboglobulin and thromboxane B2
levels in blood samples drawn through them, We recently
reported (12) the development of heparin-bonded catheters
that permit selective blood sampling with minimal artifac-
tual activation of the hemostatic system.
The present study addresses the issue of whether myo-
cardial ischemia activates platelets and induces fibrin for-
mation in the coronary circulation, Patients with severe
proximal stenoses of the left anterior descending coronary
artery were studied before, during and after sustained myo-
cardial ischemia induced by rapid atrial pacing. Catheters
with heparin-bonded surfaces were used to minimize cath-
eter-induced fibrin formation and platelet activation. To se-
lectively sample the venous effluent from the ischemic an-
terior ventricular segment, catheters were positioned in the
great cardiac vein.
The principal aim of this study was to determine whether
myocardial ischemia induced by rapid atrial pacing causes
platelet activation or fibrin formation, or both, in the coro-
nary circulation, Three independent and highly sensitive
indexes (platelet factor 4, beta-thromboglobulin and throm-
boxane B2) were used to detect in vivo platelet activation,
and fibrinopeptide A was used as an index of thrombin
action,
Methods
Patient selection. Seven patients with exertional angina
and severely stenotic lesions of the proximal left anterior
descending artery were studied. Included were six men and
one woman with a mean age of 65 years. All patients had
typical exertional angina for periods ranging from I week
to 3 years, Each patient underwent diagnostic coronary ar-
teriography for clinical indications. All patients had >70%
narrowing of the proximal left anterior descending coronary
artery, and all except one had severe triple vessel coronary
artery disease (Table I),
Patients with acute myocardial infarction or congestive
heart failure resulting from prior myocardial infarction were
excluded from the study because previous studies (7,8) have
shown that platelet factor 4, beta-thrornboglobulin and fi-
brinopeptide A levels are frequently elevated in these pa-
tients. Also excluded were patients receiving heparin or
coumarin anticoagulants agents and patients receiving an-
tiplatelet agents. Patients with thromboembolism, a pros-
thetic heart valve or a pacemaker were similarly excluded.
Each patient provided informed written consent for partic-
ipation in the study protocol, which was approved by the
Committee on Human Investigation of Columbia Univer-
sity.
Catheterization protocol. Patients were studied after an
overnight fast, and beta-adrenergic antagonists, long-acting
nitrates, and calcium channel blockers were discontinued
10 hours before catheterization. One patient received pro-
pranolol, 20 mg, 4 hours before the study and one patient
continued to receive nifedipine.
A 7F heparin-bonded, woven Dacron, bipolar electrode
catheter (Gorlin catheter, USCI Cardiology and Radiology
Division) was inserted through an 8F vascular sheath placed
percutaneously into the right internal jugular vein by the
Seldinger technique (13). The catheter tip was positioned
in the right atrium, and a control blood sample was with-
drawn. The catheter was then positioned in the coronary
sinus and was advanced into the great cardiac vein under
fluoroscopy. The positioning of the catheter tip in the great
cardiac vein was confirmed by oximetry. A heparin-bonded,
polyurethane right coronary catheter (Judkins-Schmidt type)
was then introduced through a vascular sheath inserted per-
cutaneously into the femoral artery, The catheter was ad-
vanced into the ascending aorta under fluoroscopy. Both
catheters were fil1ed with saline solution before insertion
and were inserted without guide wires. A previous study in
our laboratory (12) has shown that catheter insertion over
Table 1. Coronary Arteriographic Findings in the Seven Patients Studied
Patient Age (yr) Estimated Percent Coronary Stenosis
No. & Sex LMCA LAD LCx RCA
I 60M 70 70 100 100
2 58M 0 80 80 75
3 73M 0 100 75 99
4 60M 0 99 0 0
5 66M 0 99 50 100
6 68F 70 90 100 90
7 69M 0 90 25 100
Ant Desc = left anterior descending coronary artery; F = female; LMCA = left main coronary artery;
LAD = left anterior descending coronary artery; LCx = left circumflex coronary artery; M = male; RCA =
right coronary artery.
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guide wires causes artifactual elevation of plasma fibrino-
peptide A, beta-thromboglobulin, platelet factor 4 and
thromboxane B2 levels. Saline solution (0.9%) was infused
continuously at 1.0 milmin through the catheter lumen, ex-
cept during blood sampling. Blood samples for baseline
fibrinopeptide A, beta-thromboglobulin, platelet factor 4
and thromboxane B2 and lactate levels were then collected
from the great cardiac vein and ascending aorta.
Atrial pacing was then commenced using the bipolar
pacing electrodes on the Gorlin catheter. The heart rate was
increased in 10 beat/min increments at I minute intervals
until the patient experienced angina or attained a maximal
heart rate of 150 beats/min. The tachycardia was sustained
for 3 to 5 minutes while the patient experienced angina.
Repeat blood samples were collected simultaneously from
the great cardiac vein and ascending aorta during angina.
None of the patients were given nitroglycerin during pacing-
induced angina, and long-acting nitrates had been discon-
tinued before coronary arteriography. Immediately after blood
sample collection, pacing was discontinued and, after a 5
minute recovery period, blood sampling was repeated. The
Gorlin catheter was then withdrawn until the tip was again
positioned in the right atrium, and a final control blood
sample was obtained.
Three electrocardiographic leads (L, aVF and VI) were
monitored continuously during pacing. The electrocardio-
graphic (ECG) criteria for an ischemic response to pacing
was horizontal or downsloping ST segment depression of
~0.1 mV in the cycles immediately after termination of
pacing (14, IS). All blood samples were collected before
intracardiac pressure recordings or injection of contrast me-
dium for angiography.
Blood sample processing and radioimmunoassays. For
assay offibrinopeptide A, beta-thromboglobulin and platelet
factor 4, blood samples (9 ml) were withdrawn from the
catheters into polypropylene syringes, and immediately
transferred into a chilled 10 ml siliconized glass tube con-
taining I ml of the following anticoagulant mixture: 1,400
V/ml heparin, 1,000 V/ml aprotinin (Trasylol), 10 mM
adenosine and 20 mM theophylline in N-2-hydroxyethyl-
piperazine-N'-2-ethane sulfonic acid (HEPES)-buffered sa-
line solution (pH 7.4). The tubes were placed in melting
ice and centrifuged within I hour at 3,000 g for 20 minutes
at 4°C. The supernatant plasma was transferred to polypro-
pylene tubes and centrifuged at 49,000 g for 15 minutes at
4°C. The resulting platelet-poor plasma was stored frozen
at - 80°C until assayed.
For assay ofthromboxane B2> 3 ml of blood was collected
into 10 mg of disodium ethylenediaminetetraacetate. The
sample was centrifuged at 3,000 g for 20 minutes at 4°C
and the supernate plasma stored at - 80°C until assayed.
Fibrinopeptide A, platelet factor 4, beta-thromboglobulin
and thromboxane B2 levels were measured by radioimmu-
noassay as previously described (9,16-18).
Lactate assay. Blood samples for lactate determination
were deproteinated in iced 10% perchloric acid and assayed
by a spectrophotometric technique (Sigma Chemical Com-
pany) (19). A change in the arteriovenous lactate difference
of >0.8 mg/dl from control period to peak pacing was
considered diagnostic of myocardial ischemia (20).
Statistical analysis. Analysis of variance and other par-
ametric tests were performed after logarithmic transfor-
mation of the fibrinopeptide A, platelet factor 4, beta-throm-
boglobulin and thromboxane B2 data, because these data
have been noted to be skewed in past studies (8). For this
reason geometric rather than arithmetic means have been
used to describe the results. Probability levels were consid-
ered to be statistically significantly different at <0.05. Be-
cause fibrinopeptide A, platelet factor 4, beta-thrombo-
globulin and thromboxane B2 all reflect activation of the
hemostatic system, tests of significance for four different
variables were combined as described by Sokal and Rohlf
(21).
Results
Response to rapid atrial pacing. During rapid atrial
pacing, ST segment depression diagnostic of myocardial
ischemia was observed in all patients. ST segment depres-
sion was observed in lead I in all seven patients and in lead
aVF in two patients. Five of the seven patients experienced
angina, and pacing was terminated before 5 minutes had
elapsed in three patients because of severe chest pain. Dur-
ing pacing, lactate extraction decreased significantly in five
patients. Thus, six of the seven patients had either chest
pain or altered lactate extraction, or both, confirming the
occurrence of ischemia in response to pacing.
Fibrinopeptide A levels (Fig. 1). The mean fibrino-
peptide A level in blood withdrawn from the great cardiac
vein did not change significantly in response to ischemia
and did not differ significantly from levels in aortic blood
samples collected simultaneously, either before or during
pacing. Fibrinopeptide A levels were significantly higher (p
< 0.05) in the great cardiac vein than in the right atrium
before pacing.
Platelet factor 4 levels (Fig. 2). Mean platelet factor 4
levels in aortic and great cardiac vein blood collected during
pacing-induced ischemia and in the recovery phase did not
differ significantly from levels measured during rest con-
ditions. Platelet factor 4 levels in great cardiac vein and
aortic blood samples did not differ significantly either at
rest, during rapid atrial pacing or during recovery. Before
rapid pacing, mean platelet factor 4 levels were significantly
(p < 0.05) higher in both the great cardiac vein and the
aorta than in the right atrium.
Beta-thromboglobulin levels (Fig. 3). Mean beta-
thromboglobulin levels also were not significantly elevated
in the great cardiac vein or aorta during pacing-induced
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Discussion
Many groups of investigators (10,22-26) have postulated
that acute myocardial ischemia induces abnormal platelet
Figure 1. Fibrinopeptide A levels in plasma collected at rest.
during peak atrial pacing and after recovery (geometric mean ::!:
SEM). Samples collected with the venous catheter from the right
atrium (RA)areshown as opencircles, and from thegreat cardiac
vein (GCY) as closed circles. Samples collected from the as-
cendingaorta (Ao) through thearterial catheterare shown as open
squares. Fibrinopeptide A levels in the great cardiac vein were
not significantly elevated during pacing-induced ischemia.
ischemia or in the recovery period. Beta-thromboglobulin
levels in great cardiac vein blood samples were not signif-
icantly different from levels in the right atrium or aorta
before, during or after rapid pacing.
Thromboxane B2 levels (Fig. 4). Similarly, thrombox-
ane B2 levels did not differ significantly in the aorta, great
cardiac vein or right atrium. at rest, during pacing-induced
ischemia or in the recovery period,
Statistical analysis. The combined test of signifi cance
performed on the logarithmically transformed data indicated
no net change in the variables measured during pacing-
induced ischemia. Activation of the hemostatic system lead-
ing to a combined 50% increase in the measured levels
would have been detectable at the I% level, The actual
changes found (fibrinopeptide A, + 10%; platelet factor 4 .
- 3%; beta-thromboglobulin, - II %; and thromboxane 8 2,
+4%) indicate no detectable activation of the hemostatic
system.
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Figure3. Beta-thromboglobul in levels in plasma collected at rest.
during peak pacing and after recovery (geometric mean ::!: SEM)
show no significant change during pacing-induced ischemia. Sym-
bols and abbreviations as in Figure I.
activation in the coronary circulation. The importance of
this issue is that enhanced platelet aggregation in the coro-
nary circulation could impede blood flow in atherosclerotic
coronary arteries, resulting in further ischemia. Further-
more, thromboxane B2 generation caused by aggregated
platelets may aggravate myocardial ischemia by inducing
coronary vasoconstriction. Most important, platelet acti-
vation and fibrin formation in the coronary circulation could
induce coronary thrombosis. resulting in myocardial in-
farction.
Effect of pacing-induced ischemia on thromboxane B2
levels. This issue has become controversial. however, be-
cause recent studies of the effect of pacing-induced ischemia
on platelet activation in the coronary circulation have produced
confl icting results. Lewy et al. (10) first reported in 1980
that thromboxane 8 2 levels were elevated in the coronary
sinus blood of several patients during pacing-induced isch-
emia. Subsequently. other investigators (11,27) observed
increased thromboxane 8 2 release in patients with coronary
artery disease during pacing-induced ischemia. Recently.
Martin e[ al. (28) observed positive transmyocardial throm-
boxane 8 2 gradients in 8 of 18 patients after pacing but in
none during pacing. Lastly, Rubenstein et al. (29) reported
significant transmyocardial release of beta-thromboglobulin
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Figure2. Platelet factor4 levels in plasmacollected at rest, during
peak pacing and after recovery (geometric mean ::!: SEM) show
no significant change during pacing-induced ischemia. Symbols
and abbreviations as in Figure I.
Figure 4. Thromboxane B! levels in plasma collected at rest.
during peak pacing and after recovery (geometric mean ± SEM)
were not significantly elevated during pacing-induced ischemia.
Symbols and abbreviations as in Figure I.
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in patients with coronary artery disease studied at rest, but
other authors (30,31) reported that beta-thromboglobulin
levels are not elevated in coronary sinus blood samples in
similar patients.
Fibrin formation and platelet aggregation on catheter
surfaces. In all of these studies, blood samples were col-
lected from the coronary sinus and aorta with conventional
woven Dacron cardiac catheters. We have studied (12) the
effect of blood contact with catheter surfaces on levels of
fibrinopeptide A, platelet factor 4, beta-thromboglobulin
and thromboxane B2 in blood samples withdrawn through
cardiovascular catheters. We found that blood collected
through woven dacron catheters showed artifactual elevation
of these levels as a result of fibrin formation and platelet
aggregation on the surfaces of the catheters. Progressive
elevation of fibrinopeptide A and platelet proteins was ob-
served while the catheters remained in the venous or arterial
circulation, particularly if multiple blood samples were col-
lected through the catheters. These observations may ex-
plain why elevated thromboxane B2 levels were observed
in previous studies in both aortic and coronary sinus blood
during and after pacing (l0, II ,27).
Role of heparin-bonded catheters for collecting blood
samples. In the present study, heparin-bonded catheters
were used for collection of blood samples from the great
cardiac vein and aorta. We previously found (l2) that col-
lection of blood samples through such catheters eliminated
spurious elevation of fibrinopeptide A, platelet factor 4,
beta-thromboglobulin and thromboxane H2 caused by fibrin
formation and platelet aggregation on catheter surfaces.
Scanning electron microscopy revealed fibrin strands and
platelet aggregates on the surfaces of conventional catheters,
but not on catheters with heparin-bonded surfaces. The pas-
sivating effect of heparin bonding was shown to last for
> 30 minutes, which is a suitable time for completion of an
interventional pacing study. However, elevation of the fi-
brinopeptide A level was consistently observed after per-
cutaneous insertion of vascular sheaths. In the present study,
multiple vascular sheaths were inserted, which accounts for
the elevated baseline level of fibrinopeptide A. In both stud-
ies, the fibrinopeptide A levels were noted to decline grad-
ually over the ensuing 20 to 30 minutes.
Effect of ischemia on fibrinopeptide A and platelet
protein levels. In the present study, mean levels of fibri-
nopeptide A, platelet factor 4, beta-thromboglobulin and
thromboxane H2 in the great cardiac vein during pacing-
induced ischemia did not differ from coronary sinus levels
measured at rest or in the recovery period. Furthermore,
significant transmyocardial gradients of these levels were
not observed at rest, during pacing-induced ischemia or in
the recovery period after pacing. These data indicate that
pacing-induced ischemia does not cause the release of de-
tectable fibrinopeptide A, platelet factor 4, beta-thrombo-
globulin or thromboxane H2 into the coronary circulation
and suggest that pacing-induced ischemia does not activate
platelets or cause fibrin formation. Although the number of
patients studied was small, the combined test of significance
based on all four assays enhanced the statistical power of
this result.
Levels of jibrinopeptide A in the coronary circulation
during acute myocardial ischemia have not been reported
previously. Two recent studies (30,31) have described beta-
thromboglobulin levels in the coronary sinus blood of pa-
tients during pacing-induced myocardial ischemia. Thaulow
(30) reported that these levels were not elevated in patients
with pacing-induced ischemia, but were inexplicably ele-
vated in patients without ischemia during pacing. Verheught
et al. (31) reported that they were not elevated at rest or
during pacing-induced ischemia in patients given 5,000 units
of heparin before catheterization. In both of these studies,
blood samples were collected nonselectively from the coro-
nary sinus; with such sampling it is possible that an increased
concentration of a substance released from an area of isch-
emia could be diluted by blood draining from a nonischemic
region. To minimize this problem, in the present study we
selected patients with lesions of the proximal left anterior
descending artery and selectively catheterized the great car-
diac vein, which drains the venous effluent of the anterior
descending coronary artery. This technique should ensure
that venous blood was directly sampled from the ischemic
left ventricular segment without dilution by venous effluent
from the nonischemic segments.
To detect possible in vivo platelet activation in the present
study, two platelet proteins in addition to thromboxane B2
were measured. Determination of both platelet factor 4 and
beta-thromboglobulin levels in each sample is useful for
distinguishing in vitro from in vivo platelet release occurring
during collection and processing of blood samples (32). In
previous studies, only one platelet protein assay was per-
formed, raising the possibility that artifactual platelet acti-
vation was undetected.
The observation that jibrinopeptide A and platelet factor
4 levels were slightly, but significantly, higher in the great
cardiac vein and the aorta than in the right atrium raises
the possibility that they were continuously released into the
coronary venous effluent or released from the lungs. How-
ever, the magnitude of the elevation was slight and further
studies will be necessary to distinguish intrapulmonary from
intracoronary release. Recently, Mant et al. (33) presented
data, obtained with heparin-filled catheters, which dem-
onstrate that platelet factor 4 and beta-thromboglobulin lev-
els are not elevated at rest in coronary sinus blood of patients
with coronary artery disease; other investigators (30,31)
reported similar findings.
Summary and clinical implications. Our study dem-
onstrates that pacing-induced ischemia does not cause plate-
let activation or fibrin formation in blood draining ischemic
myocardial segments. The implication of our study is that
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stress-induced ischemia itself does not activate the coagu-
lation system in the coronary circulation . Thus, pacing-
induced ischemia will not be a useful model for studying
intracoronary platelet activation or fibrin formation asso-
ciated with spontaneous myocardial ischemia. The mech-
anism of pacing-induced angina probabl y differs consider-
ably from the mechanism of spont aneous angina occurring
at rest. Consistent with this observation is the recent report
of Fitzgerald et al. (34) that urinary metabolites of throm-
boxane were acutely increa sed in patients with unstable
angina during chest pain, but were not increased in patient s
with stable angina after exercise-induced ischemia.
We acknowledge the invaluable technical ass istance of Betty Grossman.
who performed the fibrinopeptide A, platelet factor 4 and beta-thrombo-
globulin assays. and we thank Leonard L. Norbert for expert preparation
of this manuscript.
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